This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Engelman, J. A. Search for Related Content PubMed PubMed Citation Articles by Engelman, J. A.

The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer

Author's Affiliations: ¹ Massachusetts General Hospital Cancer Center, ² Department of Systems Biology, Harvard Medical School, and ³ Department of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Requests for reprints: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown Navy Yard, 149 13th Street, Charlestown, MA 02129. Phone: 617-724-4000; E-mail: jengelman{at}partners.org.

The phosphoinositide 3-kinase signaling network is widely implicated in the pathogenesis of human cancer. This pathway is commandeered by cancer cells to promote unrestrained cellular growth and survival. In this brief review, we speculate about the uses of inhibitors of phosphoinositide 3-kinase signaling as treatments for human cancers, with an emphasis on non–small cell lung cancer.

This article has been cited by other articles:

				P. A. Bunn Jr., E. B. Haura, and J. V. Heymach Emerging Therapies for Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): e5 - e14. [Abstract] [Full Text] [PDF]